Bloomberg-reported interest has prompted Qiagen to evaluate strategic alternatives, including a potential sale, sending its shares higher. The life-science tools and diagnostics provider has held talks with multiple potential buyers and is working with advisers while its supervisory board reviews preliminary interest. The move recalls Thermo Fisher’s failed 2020 bid and later reported suitor conversations. Analysts say a transaction could reshape diagnostics consolidation; J.P. Morgan’s Casey Woodring noted investors have long viewed Qiagen as a takeout candidate. The process puts a spotlight on valuations in the molecular-diagnostics sector and potential strategic fits for larger lab-supply players.